Related Experiment Video
Updated: Oct 11, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Apoptolidin family glycomacrolides target leukemia through inhibition of ATP synthase
Benjamin J Reisman1,2, Hui Guo3,4, Haley E Ramsey5
1Department of Chemistry, Vanderbilt University, Nashville, TN, USA.
Abstract:
Cancer cells have long been recognized to exhibit unique bioenergetic requirements. The apoptolidin family of glycomacrolides are distinguished by their selective cytotoxicity towards oncogene-transformed cells, yet their molecular mechanism remains uncertain. We used photoaffinity analogs of the apoptolidins to identify the F1 subcomplex of mitochondrial ATP synthase as the target of apoptolidin A. Cryogenic electron microscopy (cryo-EM) of apoptolidin and ammocidin-ATP synthase complexes revealed a novel shared mode of inhibition that was confirmed by deep mutational scanning of the binding interface to reveal resistance mutations which were confirmed using CRISPR-Cas9. Ammocidin A was found to suppress leukemia progression in vivo at doses that were tolerated with minimal toxicity. The combination of cellular, structural, mutagenesis, and in vivo evidence defines the mechanism of action of apoptolidin family glycomacrolides and establishes a path to address oxidative phosphorylation-dependent cancers.
Insights
Apoptolidin A targets the F1 subcomplex of mitochondrial ATP synthase, inhibiting cancer cell growth. This discovery offers a new therapeutic strategy for oxidative phosphorylation-dependent cancers.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Biology
Background:
- Cancer cells possess distinct bioenergetic needs.
- Apoptolidin glycomacrolides show selective toxicity to cancer cells, but their mechanism is unknown.
Purpose of the Study:
- To elucidate the molecular mechanism of apoptolidin A's anti-cancer activity.
- To identify the specific molecular target of apoptolidin A.
Main Methods:
- Photoaffinity labeling to identify target proteins.
- Cryogenic electron microscopy (cryo-EM) for structural analysis.
- Deep mutational scanning and CRISPR-Cas9 for functional validation.
Main Results:
- Mitochondrial ATP synthase F1 subcomplex identified as the direct target of apoptolidin A.
- Cryo-EM revealed a novel shared inhibition mechanism between apoptolidin and ammocidin.
- In vivo studies demonstrated ammocidin A suppresses leukemia with minimal toxicity.
Conclusions:
- The study defines the mechanism of action for apoptolidin family glycomacrolides.
- Identified ATP synthase as a target provides a new avenue for treating oxidative phosphorylation-dependent cancers.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Intrinsic Apoptotic Pathway
Drugs that Destabilize Microtubules
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

